HALO Halozyme Therapeutics, Inc.

12.60
-0.24  -2%
Previous Close 12.84
Open 12.90
Price To book 0.00
Market Cap 1.62B
Shares 128,615,000
Volume 874,284
Short Ratio 18.30
Av. Daily Volume 1,294,050

SEC filingsSee all SEC filings

  1. 8-K - Current report 17858809
  2. 424B5 - Prospectus [Rule 424(b)(5)] 17858740
  3. 424B5 - Prospectus [Rule 424(b)(5)] 17854922
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17826759
  5. 8-K - Current report 17826690

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA June 26, 2017.
Subcutaneous rituximab
Various blood cancers
Phase 1/2 enrollment closed due to lack of efficacy.
FOLFIRINOX and PEGPH20
Pancreatic and gastric cancers
Phase 1/2 initiated July 2016
Eribulin In Combination With PEGPH20
High-Hyaluronan (HA) HER2-negative breast cancer
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 dosing initiated March 2016. Phase 2 data released January 5, 2017. Oral presentation of Phase 2 data at ASCO June 4, 2017. Abstract 4008.
PEGPH20
Pancreatic cancer
Phase 1b enrolment resumed July 2016 under revised protocol. Response rate data possible by end of 2017.
PEGPH20 in combination with KEYTRUDA
Non-small cell lung cancer (NSCLC)
Approved September 12, 2014.
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 2 topline data released 1Q 2014
HTI-501
Celluoite

Latest News

  1. Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
  2. Halozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
  3. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : May 22, 2017
  4. Why Halozyme Therapeutics, Seadrill, and Sibanye Gold Slumped Today
  5. Halozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10%
  6. Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme
  7. Halozyme Therapeutics Prices Public Offering Of Common Stock
  8. Halozyme shares fall after secondary share offering annoucned
  9. Halozyme Therapeutics Announces Public Offering Of Common Stock
  10. Blog Coverage: Omeros' Stock Jumped on Completion of IgA nephropathy Cohort and Additional Positive Results
  11. Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO
  12. Edited Transcript of HALO earnings conference call or presentation 9-May-17 8:30pm GMT
  13. Halozyme Therapeutics reports 1Q loss
  14. Halozyme Reports First Quarter 2017 Financial Results
  15. Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call
  16. Halozyme Therapeutics, Inc. – Value Analysis (NASDAQ:HALO) : April 24, 2017
  17. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : April 21, 2017
  18. If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
  19. Halozyme To Host First Quarter 2017 Financial Results Conference Call
  20. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : April 6, 2017